Jul292021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease July 29, 2021
Jun142021 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease June 14, 2021
Jun82021 Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease June 8, 2021
May52021 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development May 5, 2021
Apr262021 Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference April 26, 2021
Mar312021 Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease March 31, 2021
Mar162021 Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy” March 16, 2021
Feb112021 Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook February 11, 2021
Feb82021 Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 February 8, 2021
Dec282020 Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates December 28, 2020
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Nov62020 Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference November 6, 2020
